



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

APY29

Cat. No.:	HY-17537
CAS No.:	1216665-49-4
Molecular Formula:	C ₁₇ H ₁₆ N ₈
Molecular Weight:	332.36
Target:	IRE1
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (150.44 mM; ultrasonic and warming and heat to 60°C)
 H₂O : 5 mg/mL (15.04 mM; ultrasonic and adjust pH to 3 with HCl)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.0088 mL	15.0439 mL	30.0879 mL
	5 mM		0.6018 mL	3.0088 mL	6.0176 mL
	10 mM		0.3009 mL	1.5044 mL	3.0088 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 5 mg/mL (15.04 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 5 mg/mL (15.04 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 5 mg/mL (15.04 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC₅₀ of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain^[1].

IC₅₀ & Target

IC₅₀: 280 nM (IRE1α)

In Vitro

APY29 divergently modulates the RNase activity and oligomerization state of IRE1 α . APY29 is exerting their opposing effects on RNase activity through the same binding site. APY29 divergently affects IRE1 α oligomerization. APY29 demonstrates opposing dose-dependent effects on ER stress-induced activation of the RNase of endogenous IRE1 α ^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Transl Med. 2019 Feb 6;11(478). pii: eaau5266.
- Nat Commun. 2023 Nov 17;14(1):7441.
- Sci Adv. 2019 Apr 10;5(4):eaaw0025.
- EMBO J. 2019 Aug 1;38(15):e100999.
- FEBS J. 2019 Apr;286(7):1375-1392.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang L, et al. Divergent allosteric control of the IRE1 α endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012 Dec;8(12):982-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA